- Ciox Health has acquired Medal, Inc., a biomedical Natural Language Processing (biomed-NLP) technology company.
- The acquisition will lead Ciox to better and more quickly enable real-world data in support of research that advances patient care.
Ciox Health, a leading health technology company, today announced its acquisition of San Francisco-based biomedical Natural Language Processing (biomed-NLP) technology company, Medal, Inc., a leader in the application of AI techniques to the interrogation of unstructured medical record data. The acquisition accelerates capabilities to enable real-world data (RWD) in support of research that advances patient care.
The Real-World Data Advantage
As more pharmaceutical and research organizations look to real-world data to accelerate clinical research, reliable identification, and interpretation of phenotypic data from deep inside medical records are becoming paramount. The most relevant information resides in the unstructured data: the surgical reports, pathology reports, imaging reports, discharge summaries, and other clinician-scribed narrative text. Medal’s software helps identify, contextualize, and interpret narrative-based medical notes, leading to the creation of research-grade data sets at scale. The company’s approach to biomed-NLP and deep learning AI is guided and informed by consensus from clinical expert reviewers across therapeutic areas.
“More than 100 million medical records are retrieved and reviewed by Ciox each year from the vast majority of U.S. providers, presenting an unprecedented opportunity to actually bring a true longitudinal perspective to clinical investigation. Ciox works at the first and last mile of U.S. healthcare data,” says Andy McMurry, Ph.D., Chief Science Officer of Medal. “Using Medal AI, Ciox will reduce human expert time and increase the utility of patient data to support biomedical discovery and clinical trials research across many disease areas, including COVID-19. Combining vast biomedical knowledge sources with clinically trained Artificial Intelligence enabling human experts, we are reinventing real-world data for clinical investigation.”
Acquisition Benefits for Ciox Health
This acquisition is the third major recent announcement from Ciox’s growing Real World Data business, following two prior announcements of strategic collaborations with LabCorp and Merck. As health data remains fragmented throughout the U.S. healthcare ecosystem, Ciox is attracting interest in its RWD division from medical research organizations and other partners. This additional feature of the Ciox DataFit Platform through the acquisition of Medal will enable faster and more consistent translational research.
Why It Matters
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
“We’re proud to bolster the Ciox Real World Data offering with Medal’s technology and team,” says Pete McCabe, CEO, Ciox. “The team and the biomed-NLP product, combined with Ciox’s technology-enabled ability to create longitudinal records across EHRs and provider systems, remove the friction related to medical records-based clinical research. We will consistently supply consented, HIPAA-compliant, de-identified, research-grade RWD for complex clinical use cases to commercial researchers in pharma and biotech, as well as government sponsored researchers. The need is particularly highlighted in the COVID-19 research questions being asked by agencies like the FDA, CDC and NIH.”
Source: Hit Consultant
